Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Pancreatic Neoplasms 7Breast Neoplasms 7Colorectal Neoplasms 6Stomach Neoplasms 5Neoplasms 5Sarcoma 3Precision Cell Immunotherapy 3Ovarian Neoplasms 3Neoplasm Metastasis 3Mesothelioma, Malignant 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Hodgkin Disease 3Glioblastoma 3Esophageal Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Mesothelioma 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Ovarian Epithelial 2Virus Diseases 1

Interventions

pembrolizumab 2Cisplatin 2pralsetinib 1ficlatuzumab 1Taxes 1Pemetrexed 1Paclitaxel 1Irinotecan 1Gemcitabine 1Gefitinib 1Drug Therapy 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Glandular and Epithelial × Drug Therapy × Clear all
NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Genelux Corporation

Phase 1/2 Completed
46 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡